FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:522-523 February 14, 2002 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Casadevall, N. PubMed Citation

Whether judged by its therapeutic or economic impact, recombinant human erythropoietin (epoetin) is an extremely successful application of molecular genetic technology to the development of a therapeutic agent. Epoetin is remarkably effective in the treatment of patients with a deficiency of the hormone, especially those with uremia, in whom renal production of erythropoietin is markedly impaired. Because erythropoietin receptors occur predominantly on erythroid progenitor cells, epoetin has a high degree of specificity and no clinically significant effects on nonhematopoietic cells. Thus, its ratio of efficacy to toxicity, or therapeutic index, is matched by few, if any, other pharmacologic agents.

Until . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Maas, C., Hermeling, S., Bouma, B., Jiskoot, W., Gebbink, M. F. B. G. (2007). A Role for Protein Misfolding in Immunogenicity of Biopharmaceuticals. J. Biol. Chem. 282: 2229-2236 [Abstract] [Full Text]  
• Galliford, J. W., Malasana, R., Farrington, K. (2005). Switching from subcutaneous to intravenous erythropoietin {alpha} in haemodialysis patients requires a major dose increase. Nephrol Dial Transplant 20: 1956-1962 [Abstract] [Full Text]  
• Schonholzer, C., Keusch, G., Nigg, L., Robert, D., Wauters, J.-P. (2004). High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases. Nephrol Dial Transplant 19: 2121-2125 [Abstract] [Full Text]  
• Vartia, A., Asola, M. R., Tertti, R., Kunelius, P., Metsarinne, K. P. (2004). Two haemodialysis patients with epoetin alfa-induced pure red-cell aplasia recovered despite treatment with another epoetin preparation. Nephrol Dial Transplant 19: 1313-1316 [Full Text]  
• Henry, D. H., Bowers, P., Romano, M. T., Provenzano, R. (2004). Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine. Arch Intern Med 164: 262-276 [Abstract] [Full Text]  
• Locatelli, F., Aljama, P., Barany, P., Canaud, B., Carrera, F., Eckardt, K.-U., Macdougall, I. C., Macleod, A., Horl, W. H., Wiecek, A., Cameron, S. (2004). Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?. Nephrol Dial Transplant 19: 288-293 [Full Text]  
• Eckardt, K.-U., Casadevall, N. (2003). Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 18: 865-869 [Full Text]  
• Storring, P. L., Yuen, C-T., Skibeli, V., Nissen-Lie, G., Torjesen, P. (2003). Differences between the N-glycans of human serum erythropoietin and recombinant human erythropoietin. Blood 101: 1204-1204 [Full Text]  
• Weber, G., Gross, J., Kromminga, A., Loew, H.-H., Eckardt, K.-U. (2002). Allergic Skin and Systemic Reactions in a Patient with Pure Red Cell Aplasia and Anti-Erythropoietin Antibodies Challenged with Different Epoetins. J. Am. Soc. Nephrol. 13: 2381-2383 [Abstract] [Full Text]  
• Gershon, S. K., Luksenburg, H., Cote, T. R., Braun, M. M., Sokol, L., Prchal, J. T., Casadevall, N., Mayeux, P., Bunn, H. F. (2002). Pure Red-Cell Aplasia and Recombinant Erythropoietin. NEJM 346: 1584-1586 [Full Text]